Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
Kidney Outcomes and Preservation of Kidney Function with Obinutuzumab in Patients with Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial
Arthritis Rheumatol. 2023 DOI 10.1002/art.42734
This post hoc analysis of the Phase 2 NOBILITY trial determined that obinutuzumab plus standard of care improved the likelihood of long-term preservation of kidney function and improved kidney function with less glucocorticoid use in patients with lupus nephritis.
Keywords:
Efficacy and Safety of Telitacicept in Patients with Systemic Lupus Erythematosus: A Multicentre, Retrospective, Real-World Study
Lupus Sci. Med. 2023;10(2):e001074 DOI 10.1136/lupus-2023-001074
In this study, telitacicept add-on therapy demonstrated desirable real-world safety and efficacy profiles for the management of SLE, LN, and patients with haematological abnormalities.
Emerging Immunotherapeutic Strategies for Cutaneous Lupus Erythematosus: An Overview of Recent Phase 2 and 3 Clinical Trials
Expert Opin Emerg Drugs 2023; 20:1-17 DOI: 10.1080/14728214.2023.2273536 Epub ahead of print
Current treatments for refractory CLE are insufficient, often leading to suboptimal disease control, and demanding escalated therapies associated with systemic toxicities. However, recent Phase 2 & 3 trials offer promising results, suggesting new therapeutics approved for CLE are on the horizon.
EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update
Ann Rheum Dis 2023; 2023-224762 DOI: 10.1136/ard-2023-224762 Epub ahead of print
The objective of this international task force was to update the EULAR recommendations for the management of SLE. The Task Force agreed on 5 overarching principles and 13 recommendations, generating an overall framework for the approach to a patient with SLE. The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.
Keywords:
Repeat Kidney Biopsy Findings of Lupus Nephritis Patients in Clinical Remission Treated with Mycophenolate Associated with Belimumab or Mycophenolate Plus Standard of Care Therapy. A “Post-hoc" Analysis of Participants in the BLISS-LN and Open Label Extension Study Belonging to a Single Center
doi: 10.1177/09612033231204070 Epub ahead of print
Single-centre study concludes that adding belimumab to the standard of care treatment with mycophenolate (MMF) increases the possibility of achieving a complete clinical response (CCR), complete histological response (CHR), and a lower rate of relapses during treatment and long follow-up.
Impact of Low Disease Activity, Remission, and Complete Remission on Flares Following Tapering of Corticosteroids and Immunosuppressive Therapy in Patients with Systemic Lupus Erythematous: A Multinational Cohort Study
The Lancet Rheumatology, 2023, Volume 5, Issue 10, e584 - e593 DOI: https://doi.org/10.1016/S2665-9913(23)00209-6
In this study, tapering of corticosteroids or immunosuppressive therapy in patients in LLDAS, remission, or complete remission was associated with excess flares versus continuing with therapy. Tapering in complete remission was associated with lower odds of flares compared with tapering in LLDAS or remission. In addition, patients with longer sustained duration of LLDAS or remission at the time of tapering had lower odds of flare and longer time to flare versus those with a shorter duration of LLDAS or remission.
Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases
J Pharmacol Exp Ther. 2023 doi: 10.1124/jpet.123.001744 Epub ahead of print
Preclinical evidence indicates a glucocorticoid (GC)-sparing potential for toll-like receptor (TLR)7/8 inhibitor compounds, suggesting TLR7/8i may offer a new strategy for the treatment of autoimmune diseases.
Health Related Quality of Life, Remission and Low Lupus Disease Activity State in Patients with Systemic Lupus Erythematosus
Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead407 Epub ahead of print
One of the first studies to investigate associations between disease activity and QoL, using validated generic and disease-specific PRO questionnaires, found that DORIS remission and LLDAS were associated with significant and clinically relevant higher QoL in most PRO domains of the LupusPRO (disease specific) and SF-36 (generic) questionnaires, but not with LupusQoL and SLEQOL disease-specific questionnaires.
Effect of Belimumab on Kidney-related Outcomes in Patients with Lupus Nephritis: Post Hoc Subgroup Analyses of the Phase 3 BLISS-LN Trial
Nephrol Dial Transplant. 2023 doi: 10.1093/ndt/gfad167 Epub ahead of print.
These data highlight the consistent benefit of belimumab versus placebo, combined with standard therapy, on kidney outcomes in both newly diagnosed and relapsed patients, and regardless of the use of GC pulses at induction.
SGLT2 Inhibitors Alleviated Podocyte Damage in Lupus Nephritis by Decreasing Inflammation and Enhancing Autophagy
Ann Rheum Dis. 2023 DOI: 10.1136/ard-2023-224242
Data revealed a renoprotective effect of SGLT2 inhibitors by reducing proteinuria and preserving renal function in the murine MRL/lpr lupus model.